United States - English - NLM (National Library of Medicine)

golden state medical supply, inc. - disopyramide phosphate (unii: n6bom1935w) (disopyramide - unii:gfo928u8mq) - disopyramide phosphate capsules are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. because of the proarrhythmic effects of disopyramide, its use with lesser arrhythmias is generally not recommended. treatment of patients with asymptomatic ventricular premature contractions should be avoided. initiation of disopyramide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. disopyramide phosphate capsules are contraindicated in the presence of cardiogenic shock, preexisting second- or third-degree av block (if no pacemaker is present), congenital q-t prolongation, or known hypersensitivity to the drug.

United States - English - NLM (National Library of Medicine)

pfizer laboratories div pfizer inc - disopyramide phosphate (unii: n6bom1935w) (disopyramide - unii:gfo928u8mq) - disopyramide 100 mg - norpace and norpace cr are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. because of the proarrhythmic effects of norpace and norpace cr, their use with lesser arrhythmias is generally not recommended. treatment of patients with asymptomatic ventricular premature contractions should be avoided. initiation of norpace or norpace cr treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. norpace cr should not be used initially if rapid establishment of disopyramide plasma levels is desired. antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. norpace and norpace cr are contraindicated in the presence of cardiogenic shock, preexisting second-or third-degree av block (if no pacemaker is present), congenital q-t prolongation, or known hypersensitivity to the drug.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - disopyramide - oral capsule - 100mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - disopyramide - oral capsule - 150mg

United States - English - NLM (National Library of Medicine)

carilion materials management - disopyramide phosphate (unii: n6bom1935w) (disopyramide - unii:gfo928u8mq) - disopyramide phosphate is indicated for the treatment of documented ventricular arrhythmias such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. because of the proarrhythmic effects of disopyramide phosphate, its use with lesser arrhythmias is generally not recommended. treatment of patients with asymptomatic ventricular premature contractions should be avoided. initiation of disopyramide phosphate treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. disopyramide phosphate is contraindicated in the presence of cardiogenic shock, preexisting second- or third-degree av block (if no pacemaker is present), congenital q-t prolongation, or known hypersensitivity to the drug.

Canada - English - Health Canada

sanofi-aventis canada inc - disopyramide (disopyramide phosphate) - tablet (extended-release) - 250mg - disopyramide (disopyramide phosphate) 250mg - class ia antiarrythmics

United States - English - NLM (National Library of Medicine)

carilion materials management - disopyramide phosphate (unii: n6bom1935w) (disopyramide - unii:gfo928u8mq) - disopyramide 150 mg - norpace and norpace cr are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. because of the proarrhythmic effects of norpace and norpace cr, their use with lesser arrhythmias is generally not recommended. treatment of patients with asymptomatic ventricular premature contractions should be avoided. initiation of norpace or norpace cr treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. norpace cr should not be used initially if rapid establishment of disopyramide plasma levels is desired. antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. norpace and norpace cr are contraindicated in the presence of cardiogenic shock, preexisting second- or third-degree av block (if no pacemaker is present), congenital q-t prolongation, or known hypersensitivity to the drug.

United States - English - NLM (National Library of Medicine)

carilion materials management - disopyramide phosphate (unii: n6bom1935w) (disopyramide - unii:gfo928u8mq) - disopyramide 100 mg - norpace and norpace cr are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. because of the proarrhythmic effects of norpace and norpace cr, their use with lesser arrhythmias is generally not recommended. treatment of patients with asymptomatic ventricular premature contractions should be avoided. initiation of norpace or norpace cr treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. norpace cr should not be used initially if rapid establishment of disopyramide plasma levels is desired. antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. norpace and norpace cr are contraindicated in the presence of cardiogenic shock, preexisting second- or third-degree av block (if no pacemaker is present), congenital q-t prolongation, or known hypersensitivity to the drug.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmaco australia ltd - disopyramide, quantity: 150 mg - capsule, hard - excipient ingredients: magnesium stearate; maize starch; purified talc; gelatin; titanium dioxide; pregelatinised maize starch - management of documented ventricular arrhythmias, e.g. sustained ventricular tachycardia, which are judged to be life threatening. because of its proarrhythmic potential, the use of disopyramide is not recommended for lesser arrhythmias. treatment of asymptomatic ventricular premature contractions should be avoided. in patients with structural heart disease, proarrhythmia and cardiac decompensation are a special risk associated with antiarrhythmic drugs. special caution should be exercised when prescribing disopyramide for these patients. (see precautions.)

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmaco australia ltd - disopyramide, quantity: 100 mg - capsule, hard - excipient ingredients: magnesium stearate; maize starch; purified talc; gelatin; titanium dioxide; indigo carmine; iron oxide yellow; pregelatinised maize starch - management of documented ventricular arrhythmias, e.g. sustained ventricular tachycardia, which are judged to be life threatening. because of its proarrhythmic potential, the use of disopyramide is not recommended for lesser arrhythmias. treatment of asymptomatic ventricular premature contractions should be avoided. in patients with structural heart disease, proarrhythmia and cardiac decompensation are a special risk associated with antiarrhythmic drugs. special caution should be exercised when prescribing disopyramide for these patients. (see precautions.)